| Structural highlights
4ny9 is a 1 chain structure. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
| | Ligands: | ,
| | Resources: | FirstGlance, OCA, RCSB, PDBsum |
Publication Abstract from PubMed
High affinity, functionally potent, urea-based antagonists of CCR1 have been discovered. Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 (29), which entered clinical trials for the treatment of rheumatoid arthritis.
The Discovery of CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis.,Santella J, Duncia JV, Gardner D, Wu H, Dhar MT, Cavallaro CL, Tebben AJ, Carter PH, Barrish JC, Yarde M, Briceno S, Cvijic ME, Grafstrom R, Liu R, Patel S, Watson A, Yang G, Rose A, Vickery R, Caceres Cortes J, Caporuscio C, Camac D, Khan J, An Y, Foster W, Davies P, Hynes J J Med Chem. 2014 Aug 7. PMID:25101488[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Santella J, Duncia JV, Gardner D, Wu H, Dhar MT, Cavallaro CL, Tebben AJ, Carter PH, Barrish JC, Yarde M, Briceno S, Cvijic ME, Grafstrom R, Liu R, Patel S, Watson A, Yang G, Rose A, Vickery R, Caceres Cortes J, Caporuscio C, Camac D, Khan J, An Y, Foster W, Davies P, Hynes J. The Discovery of CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis. J Med Chem. 2014 Aug 7. PMID:25101488 doi:http://dx.doi.org/10.1021/jm5003167
|
